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IntroductIon
Hypertension in pregnancy (HTNP) represents a lead-
ing cause of maternal, fetal and neonatal morbidity 
and mortality worldwide. HTNP is defined as systolic 
blood pressure (SBP) ≥ 140mmHg or diastolic blood 
pressure (DBP) ≥ 90mmHg in at least two different 
measurements during pregnancy1. Hypertensive dis-
orders in pregnancy are quite frequent. According to 
epidemiological studies, the prevalence of hyperten-
sion in pregnant women in Western Europe reaches 
a percentage of 15%2, whereas in the USA HTNP ap-
pears in 5-7% of stated births3. A significant propor-
tion of pregnant women also present heart disorders 
and pulmonary hypertension. As HTNP may also be 
combined with other disorders, such as diabetes mel-
litus, the contribution of more medical specialties -not 
only the obstetrician- is needed, in order to achieve a 
better and safer supervision of pregnant women.
Early diagnosis and treatment to minimize the 
risk of severe complications, such as eclampsia and 
HELLP syndrome (Haemolysis, Elevated Liver en-
zymes levels and Low Platelets), is of fundamental 
significance. Postnatal care and monitoring of moth-
ers and neonates are also important. In cases of births 
characterized by a small increase in BP (less than 30 
mmHg in SBP and 15mmHg in DBP), strict super-
vision by a specialized internist is recommended, al-
though the risk of complications is not significant4.
Predisposing factors for HTNP
HTNP is a multifactorial disorder. Despite insuffi-
cient knowledge related to the exact genetic and en-
vironmental mechanisms involved in its pathogenesis, 
many risk factors have been implicated (Table 1).
Regarding environmental factors, increased body 
weight and smoking are included. Increased Body 
Mass Index (BMI) is tightly related to the occurrence 
of mild hypertension and/or preeclampsia but not with 
severe forms of these disorders5. On the other hand 
and in contrast to previous knowledge, smoking seems 
Review and CommentaRy
Hypertension in pregnancy:  
classification, diagnosis and treatment.
Niki Katsiki, Dimitrios Godosis, Spyridon Komaitis, Apostolos Hatzitolios
Division of Vascular Diseases and Hypertension, 1st Propedeutic Department of Internal Medicine,  
AHEPA University Hospital, Aristotle University of Thessaloniki, Greece
ABStrAct: Hypertension in Pregnancy (HTNP) is defined as systolic blood pressure ≥ 140mmHg or diastolic blood pres-
sure ≥ 90mmHg in at least two different measurements during pregnancy. According to guidelines, HTNP is classified into 
four or more individual categories. These categories include chronic hypertension, gestational hypertension, pre-existing 
hypertension plus superimposed gestational hypertension with proteinuria, antenatally unclassified hypertension and preec-
lampsia. Although the exact causes and pathogenetic mechanisms of HTNP are not fully elucidated, the severity of the pos-
sible complications, including eclampsia and HELLP syndrome, require the maximum alertness. Physicians should consider 
HTNP as a crucial maternal, fetal and neonatal morbidity and mortality factor. Early detection and treatment are of major 
importance and should be provided in every case. In the present review the potential pathogenetic mechanisms, categories 
and therapeutic interventions for HTNP are discussed, according to up-to-date data. 
Key Words: Hypertension, Pregnancy, Preeclampsia, HELLP syndrome.
Corresponding author: Apostolos Hatzitolios Associate Professor of Internal Medicine, 1st Propedeutic Department of In-
ternal Medicine, Aristotle University of Thessaloniki, AHEPA University Hospital, Stilponos Kyriakidi str. 1 546 36, Thes-
saloniki, Tel. 2310 993480, 6937017432, Fax: 2310 994918, email: axatzito@med.auth.gr
10 Aristotle University Medical Journal, Vol. 37, Issue 2, June 2010
to reduce the risk of preeclampsia through reduced ex-
pression of specific angiogenic factors, such as sFLt1 
(soluble FMS-like tyrosine kinase-1) and PIGF (pla-
cental growth factor)6. Moreover, epidemiological 
studies correlate HTNP with socioeconomic data, as 
its prevalence is significantly higher in women with 
lower socioeconomic level. The absence of normal 
midpregnancy decrease in DBP has also been reported 
in these women7.
As far as genetic and biochemical factors are con-
cerned, low levels of renin, angiotensin II and aldos-
terone, along with abnormal renin - aldosterone ra-
tio have been observed in a percentage of pregnant 
women with preeclampsia8. Polymorphisms of the 
synthetase of endothelial NO gene (eNOS gene)9 and 
interleukin-6 gene (IL-6) have also been implicated 
in HTNP pathogenesis10. It seems that such polymor-
phisms in conjunction with disorders in plasma levels 
of antioxidant factors, such as glutathione (GSH), lead 
to increased oxidative stress during pregnancy and 
subsequent alterations in the uteroplacental flow11.
Effects of physiological adaptation of maternal or-
ganism during pregnancy
During pregnancy, mother’s organism enters a dy-
namic phase of interaction with many factors, leading 
to systemic changes. These changes are physiologi-
cal and strictly controlled by autonomous hormone 
cycles. Due to augmented needs for oxygenation and 
subsequent alterations in the cardiovascular system, 
an increased blood flow in the uteroplacental circula-
tion is attained in order to achieve adequate nutrition 
to the fetus12,13,14,15.
As a result of the above adaptations, an increase 
in plasma volume occurs after the 5th week of preg-
nancy, reaching its peak during the 33rd week. More-
over, a 40% rise in ejection fraction is observed dur-
ing that period, accompanied by a midpregnancy SBP 
fall. During the last trimester of pregnancy, the turgid 
uterus compresses inferior vena cava, therefore caus-
ing hypotensive symptoms, especially when changing 
body position from sitting to standing (inferior vena 
cava syndrome)16.
Furthermore, vaginal delivery is associated with 
important changes in maternal circulation parameters. 
In particular, pain at birth causes a raise of about 50% 
in heart rate and in cardiac output (CO), along with an 
increase of  > 20% in BP. Especially when the embryo 
exits the mother’s uterus, SBP may reach the level of 
200 mmHg through Valsalva mechanism. At the early 
postnatal period, venous decongestion, blood flow 
from the uterus to systemic circulation and redistribu-
tion of organism’s water, lead to enhanced stroke vol-
ume (SV) and CO with subsequent decrease in heart 
rate16. Finally, cardiopulmonary function returns to its 
pre-pregnancy levels at the 12th postnatal week.
Table 1. Risk factors for the appearance of HTNP.
Mother’s age (< 16 or >35 years)
First gestation
Hereditary predisposition
Preeclampsia/eclampsia at an earlier gestation
Pre-existing-chronic hypertension 
Diabetes mellitus, increased insulin intolerance
High body mass index
Increased coagulability
Renal disorders 
Autoimmune diseases
Low socioeconomic level
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Classification of HTNP
According to the recent guidelines of the European 
Society of Hypertension (ESH) and the European So-
ciety of Cardiology (ESC), [1] there are four catego-
ries of HTNP, summarized at Table 2. 
Chronic (pre-existing) hypertension
Chronic hypertension is defined as BP ≥ 140/90mmHg 
that either predates pregnancy or develops before 20 
weeks of gestation1. About 95% of pregnant women 
with chronic hypertension never develop any com-
plications throughout pregnancy. However, in elder 
pregnant women (especially in those with coexisting 
disease predisposing to preeclampsia), a higher risk 
of complications is expected4. Chronic hypertension 
usually persists more than 42 days post partum1.
Gestational hypertension
Gestational hypertension develops after 20 weeks of 
gestation and, in most cases, it resolves within 42 days 
post partum. This pregnancy-induced form of hyper-
tension is not associated with proteinuria1. The de-
velopment of gestational hypertension is physiologi-
cal and characterized by low risk for complications. 
Therefore, there is no absolute indication for medical 
treatment in every pregnant woman with an increase 
in BP. However, placental disorders may co-exist with 
gestational hypertension, thus an extensive supervi-
sion is required in such cases, as about half of women 
in this category finally develop preeclampsia (PE)16.
Pre-existing hypertension plus superimposed gesta-
tional hypertension with proteinuria
Pre-existing hypertension is associated with further 
worsening of BP after 20 weeks of gestation, followed 
by proteinuria (≥ 3g/24h)1.
Antenatally unclassified hypertension
It is defined as hypertension with or without systemic 
disorders, developed after the 20th week of pregnancy, 
with no prior BP measurements known1. Under these 
circumstances, reassessment is necessary at or after 
42 days post partum: if hypertension is resolved, it is 
characterized as gestational hypertension. If it is not 
resolved, then it is classified as pre-existing hyperten-
sion1.
The American College of Obstetricians and Gyne-
cologists (ACOG) also includes PE and PE with pre-
existing chronic hypertension in the classification of 
HTNP17.
Preeclampsia (PE)
PE is characterized by the development of hyperten-
sion and proteinuria after the 20th week of gestation18. 
The typical definition of PE includes proteinuria 
> 0,3g/24h accompanied with hypertension. However, 
in some cases, there may be no proteinuria. 
According to Walker “Preeclampsia is the result 
of an initial placental trigger, which has no adverse 
effect on the mother and a maternal systemic reaction 
that produces the clinical signs and symptoms of the 
disorder”19. Many factors are implicated in the devel-
opment of PE, both preconceptional and pregnancy-as-
sociated (Table 3)20. Abnormal placental implantation 
due to defects in trophoblasts (deficient trophoblastic 
migration and incvasion) and spiral arterioles (reten-
tion of musculoelastic media) seems to play an impor-
tant role in the pathogenesis of PE, as cytotrophoblas-
tic centers in that region are not normally developed, 
leading to uteroplacental hypoperfusion16,20.
Regarding the influence of environmental factors 
in the pathogenesis of PE, high BMI combined with 
low vascular resistance is associated with late PE epi-
Table 2. Classification of HTNP.
1. Chronic (pre-existing) hypertension (>140/90) that either predates pregnancy or develops before 20 
    weeks of gestation
2. Gestational hypertension (without proteinuria)
3. Pre-existing hypertension plus superimposed gestational hypertension with proteinuria
4. Antenatally unclassified hypertension
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sodes, whereas women with low BMI usually menifest 
early episodes of PE21.
It has been suggested that, following the defec-
tive placental perfusion, circulating factors, probably 
originated in the placenta, such as sFLt122 and soluble 
endoglin23, are responsible for the clinical manifesta-
tions of PE, reflecting widespread endothelial dys-
function, vasoconstriction and end-organ ischemia20. 
Therefore, the pathogenesis of PE is divided into two 
stages: first, placental abnormalities and second, ma-
ternal systematic reaction.
The systemic features of PE can vary from mild 
cases with little systemic involvement, to multiorgan 
failure19. Activation of intravascular coagulation and 
subsequent fibrin deposition maybe responsible for 
much of the eventual organ damage seen in severe 
PE, including proteinuria and decreased GFR from 
the kidneys, seizures and coma from CNS, abnor-
Table 3. Risk factors for preeclampsia (PE).
Preconceptional or chronic risk factors Exogenous factors
Partner-related risk factors Smoking (decreases risk)
Stress, work-related psychosocial strain
Inadequate diet
Nulliparity, primipaternity
Limited sperm exposure, teenage pregnancy, donor insemina-
tion
Partner who fathered a preeclamptic pregnancy in another 
woman
Either parent the product of a pregnancy complicated by PE 
Maternal-specific risk factors
History of previous PE
Increasing maternal age
Longer interval between pregnancies
Family history
Black or Hispanic race
Patient requiring oocyte donation
Physical inability
Presence of specific underlying disorders
Chronic hypertension and renal disease
Obesity, insulin resistance, low maternal birth weight
Gestational diabetes, type 1 diabetes mellitus
Activated protein C resistance (factor V Leiden), protein S de-
ficiency
Antiphospholipid antibodies
Hyperhomocysteinemia
Pregnancy-associated risk factors
Multiple pregnancy
Urinary tract infection
Structural congenital anomalies
Hydrops fetalis
Chromosomal anomalies (trisomy 13, triploidy)
Hydatidiform moles
(Kaplan N, Victor R. Hypertension with pregnancy and the pill. In Kaplan N, Victor R, eds. Kaplan’s Clinical Hypertension. 
Philadelphia: Lippincott Williams and Wilkins, 2010: 410-29).
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mal liver function and local pain from the liver and 
consumptive coagulopathy from the blood20. PE may 
appear as a simple headache, sometimes with optical 
disorders due to cortical blindness, which vary from 
low vision to acute loss of vision. In severe cases, 
while PE progress to eclampsia, neurologic features 
of hypertensive encephalopathy and in particular sei-
zures are also added to the above symptoms, due to 
both vasospasm and cerebral oedema that reflects an 
increase in cerebral blood flow with a failure of auto-
regulation20. Cardiopulmonary system may also par-
ticipate with symptoms such as dyspnoea and angina. 
Upper abdominal pain is not rare, while an increase 
in hepatic enzymes and creatinine and/or decrease in 
platelet count are reported. 
The severity of PE depends on different factors, 
such as the severity of hypertension, the early devel-
opment of gestational hypertension and the presence 
of oliguria, proteinuria ≥ 5g/24h, thrombocytopenia 
(< 100000x 109/L), hepatic disorders, haemolysis, hy-
peruricemia and neurological disorders17.
PE represents an independent risk factor for gesta-
tional hypertension, which appears as a complication 
of preeclampsia in about 2%-8% of pregnancies. PE 
develops during gestation and is characterized by mild 
symptoms, usually resolving within 24-48 hours after 
delivery. Rarely, a PE episode may persist until the 
10th day post-partum. In 25% of cases, PE is associ-
ated with a low neonatal weight (< 1500g)24,25.
Guidelines for the diagnosis of PE
In order to prevent unwanted outcomes, every preg-
nancy should be considered as a potentially dangerous 
one for the appearance of PE and appropriate labora-
tory tests should be performed. Important risk factors 
include proteinuria exceeding 0,3g/24h, thrombocy-
topenia and high levels of hepatic enzymes, creati-
nine, plasma proteins, lactate dehydrogenase (LDH) 
and uric acid25,26. Moreover, inversion of BP’s circa-
dian rhythm after a 24h ambulatory BP monitoring is 
an indication of severe PE. In general, women with 
the following features should be more closely evalu-
ated and monitored20: first pregnancy, previous PE, 
≥10 years since last baby, BMI ≥ 35, family history 
of PE, patient had low birth weight, DBP ≥ 80mmHg, 
proteinuria (≥ + on more than one occasion and 
≥ 0,3g/24h), multiple pregnancy, underlying medical 
condition (preexisting hypertension, diabetes, renal 
disease, presence of antihypertensive phospholipid 
antibodies).
Uterine Doppler ultrasonography may reveal utero-
placental exudation. This finding in combination with 
the development and plasticity of the endometrium, 
is of great importance for the early diagnosis of PE 
in patients with HTNP27. In cases with suspected ab-
normal uteroplacental blood flow, pretreatment with 
aspirin (at a dose of 100mg/day) is recommended, in-
dependently of the final appearance or absence of PE. 
This therapeutic strategy seems to improve blood flow 
even though the exact time of initiation of antiplate-
let treatment, the appropriate dosage and the specific 
patient groups that would benefit more are yet to be 
determined28.
HELLP syndrome
HELLP syndrome is a metabolic disorder character-
ized by hemolysis (abnormal blood smear, LDH > 
600 U/L, elevated indirect bilirubin), elevated hepatic 
enzymes (transaminases > 70 U/L) and thrombocy-
topenia (platelets < 150.000)29. The syndrome occurs 
in approximately 10% of patients with PE and is as-
sociated with significant morbidity and mortality for 
both mother and fetus30. Common presenting com-
plaints are right upper quadrant or epigastric pain, 
nausea and vomiting29. Many patients have a history 
of malaise or non-specific symptoms suggesting an 
acute viral syndrome30. The syndrome shares many 
features with the haemolytic uremic syndrome and 
thrombotic thrombocytopenic purpura20. The presence 
of HELLP syndrome in pregnancy should be inves-
tigated and handled with caution, as it is frequently 
associated with serious complications both maternal 
(acute renal failure, hemorrhage) and neonatal (acute 
respiratory failure, hypoxic damage due to placental 
abruption, low birth weight, sudden neonatal death), 
along with disorders during delivery16,29-31. Corticos-
teroids may be used32, however delivery is indicated 
if the syndrome occurs after the 34th gestational week 
or the fetal and/or maternal conditions deteriorate20. 
Subsequent pregnancies in patients with HELLP syn-
drome carry a high risk of complications such as PE, 
recurrent HELLP, prematurity, intrauterine growth re-
tardation and perinatal mortality29.
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Treatment of HTNP
Ensuring a safe pregnancy and delivery should be the 
first priority for the attending physician. The condi-
tion of both mother and fetus must be monitored for 
the prevention of a premature birth, including mea-
surement of BP, upper abdominal ultrasound and bio-
chemical tests for the mother and uterine doppler ul-
trasonography and CTG (CardioTocoGraphy) for the 
fetus33. Postnatal care of the mother is also of signifi-
cant importance, especially when a future pregnancy 
is intended16. 
Treatment strategy of HTNP is not yet globally 
determined and is mainly based on the experience of 
the attendant doctor. According to recent ESH/ESC 
guidelines and their latest reappraisal34, non-pharma-
cological management (including close supervision 
and restriction of activities) should be considered for 
pregnant women with SBP = 140-149 mmHg or DBP 
= 90-95 mmHg. In the presence of gestational hyper-
tension (with or without proteinuria) drug therapy is 
indicated at BP ≥ 140/90 mmHg, but in the case of pre-
existing hypertension without organ damage, thresh-
old for drug therapy may be 150/95 mmHg. Levels of 
SBP ≥ 160-170 mmHg or DBP ≥ 110 mmHg should 
be considered an emergency requiring hospitalisation. 
In cases of mild hypertension, drug therapy could be 
more harmful than beneficial26,35-37. Moreover, a rapid 
decrease in BP during pregnancy may impair utero-
placental perfusion and thereby put at risk fetal de-
velopment, even leading to intrauterine death. Serious 
complications may also appear in women with diabe-
tes mellitus type 1 or 2. Therefore, these cases should 
be treated with great caution38,39.
The comparative benefit of different treatment 
strategies in women with chronic hypertension with-
out other aggravating factors and in women with PE 
is not well studied. Non-pharmacological measures, 
such as low salt diet, limitation of activities and bed 
rest in the left lateral position, although advised, have 
not been proven effective enough in the treatment of 
hypertension during pregnancy40. 
Drug therapy
No consensus on treatment strategy (drugs, initia-
tion and duration of therapy) for severe hypertension 
during pregnancy is available. In clinical practice, 
widely accepted limits for initiation of treatment 
are SBP ≥ 150 mmHg and DBP > 95 mmHg. This 
threshold should be lower (140/90 mmHg) in women 
with known hypertension or coexistent hypoclini-
cal organic damage1. An increase of SBP ≥ 170 or 
DBP ≥ 110 mmHg represents an urgent situation and 
requires hospital treatment for the pregnant woman1. 
According to several researchers, target of therapy is 
SBP < 125mmHg and DBP = 90-100 mmHg33,41.
Drug treatment depends on the severity of hy-
pertension and the urgency of the situation. In cases 
of non-severe hypertension, peros administration 
of a-methyldopa is the first choice. In several stud-
ies, a-methyldopa has been proven safe for the fetus 
and neonate. However, in 15% of the mothers tak-
ing a-methyldopa side effects such as mouth dryness, 
drowsiness and depression, may appear36,42,43.
Selective b-blockers (atenolol, metoprolol, la-
betalol) and calcium ion channels antagonists (nife-
dipine sustained release, nitrendipine) are second-line 
drugs. Concerns for the teratogenicity of these drugs 
are not confirmed by the latest studies44. However, 
when prescribing atenolol, the doctor should be cau-
tious because this drug seems to be related to intrauter-
ine growth retardation, especially when it is used dur-
ing the first and second trimester of the pregnancy33,45. 
Overall, b-blockers should be used exclusively during 
the third trimester in order to reduce the possibility of 
fetal growth disorders, except for those cases where 
BP is not controlled by the use of other antihyperten-
sive agents, such as a-methyldopa or hydralazine17.
Hydralazine is administered either peros, in cases 
of chronic hypertension, or parenterally, in cases of 
acute hypertensive crisis46. As hydralazine may cause 
side effects like headache, palpitations and dizziness, 
especially when administered as monotherapy, the 
co-administration of a-methyldopa or b-blockers is 
recommended47. In a meta-analysis of clinical stud-
ies, fetal side effects of hydralazine, such as placental 
abruption, heart rate disorders and low APGAR score 
have been reported. However, these data are not ef-
ficient enough to exclude the use of hydralazine in 
clinical practice48. On the contrary, a recent Canadian 
study showed that hydralazine along with labetalol are 
the most commonly used, parenterally administrated, 
antihypertensive drugs for the management of severe 
HTNP49.
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Intravenous infusion of sodium nitroprusside is 
useful in hypertensive crises, but prolonged adminis-
tration should be avoided (fetal cyanide poisoning). 
Intravenous reduction of BP in these cases should not 
be greater than 25% of the initial value during the 
first hours, gradually reaching the level of 160/100 
mmHg50.
Magnesium sulphate remains the drug of choice 
for the treatment of preeclampsia and prevention of 
eclamptic convulsions51. Furthermore, it exerts neu-
roprotective properties to the fetus52, although fetal 
toxic effects have been also reported when the drug 
is given in high doses53. Alternative antihypertensive 
agents may provide additional benefit in the manage-
ment of hypertension in preeclamptic patients. For 
example, in PE with pulmonary oedema, nitroglycer-
ine is preferred. Diuretics are contraindicated because 
plasma volume is reduced in PE. Only furosemide 
may be used, under strict control of water-electrolyte 
balance1. 
ACE inhibitors and angiotensin II antagonists are 
strictly prohibited as they have been associated with 
serious fetal side effects, such as abortion, intrauter-
ine growth restriction and death, and neonatal renal 
failure1,54,55. No current clinical trials regarding the use 
of renin receptor blockers like aliskiren are available. 
During the peripartum period, the appropriate drug 
therapy should be decided according to drug’s con-
centration in breast milk. A-methyldopa, metoprolol, 
labetalol and ACE inhibitors are completely safe, 
although the latter may impair renal function of the 
newborn33,56,57.
Administration of possibly dangerous agents (ACE 
inhibitors, angiotensin II antagonists, atenolol) should 
be discontinued before conception in women treated 
for hypertension. If high BP levels persist, safer an-
tihypertensive agents, such as a-methyldopa and la-
betalol, should be used17.
concLuSIon 
HTNP represents an important factor of maternal, fetal 
and neonatal morbidity and mortality worldwide. The 
exact environmental and genetic factors contributing 
to the pathogenesis of the different forms of HTNP are 
not fully elucidated. Early diagnosis and treatment is 
of invaluable importance and may prevent serious ob-
stetrical complications. Proper collaboration between 
the obstetrician-gynaecologist, the internist and other 
specialists will help towards this direction. 
Uterine doppler ultrasonography is particularly 
useful for the monitoring of the intrauterine growth 
disorders. Drug treatment must be individualized, ac-
cording to both the available guidelines and the dis-
tinctiveness of each case. Generally, drug therapy is 
recommended in cases of severe hypertension, with 
a-methyldopa being the drug of choice. In women pre-
senting with severe symptoms, especially in the case 
of life-threatening eclampsia or HELLP syndrome, 
caesarean delivery is recommended, independently of 
fetal viability. Finally, intensive postnatal monitoring 
of the mother is of significant importance.
16 Aristotle University Medical Journal, Vol. 37, Issue 2, June 2010
  1. Mancia G, De Backer G, Dominiczak A, Cifkova R, 
Fagard R, Germano G, et al. 2007 Guidelines for the 
management of arterial hypertension: the Task Force 
for the management of arterial hypertension of the 
European Society of Hypertension (ESH) and of the 
European Society of Cardiology (ESC). J Hypertens 
2007;25: 1105-87.
  2. Cunningham FG, Lindheimer MD. Hypertension in 
pregnancy. N Engl J Med 1992;326: 927-32.
  3. Lindheimer MD, Taler SJ, Cunningham FG; American 
Society of Hypertension. ASH position paper: hyper-
tension in pregnancy. J Clin Hypertens (Greenwich) 
2009;11: 214-25.
  4. Brown MA, Lindheimer MD, de Swiet M, Van Ass-
che A, Moutquin JM. The classification and diagnosis 
of the hypertensive disorders of pregnancy: statement 
from the International Society for the Study of Hyper-
tension in Pregnancy (ISSHP). Hypertens Pregnancy 
2001;20: IX-XIV.
  5. Bodnar LM, Catov JM, Klebanoff MA, Ness Rb, Rob-
erts JM. Prepregnancy body mass index and the occur-
rence of severe hypertensive disorders of pregnancy. 
Epidemiology 2007;18: 234-9.
  6. Jeyabalan A, Powers RW, Durica AR, Harger GF, Rob-
erts JM, Ness RB. Cigarette smoking and angiogenic 
factors in pregnancy and preeclampsia. Am J Hyper-
tens 2008;21: 943-7.
  7. Silva LM, Steegers EA, Burdorf A, Jaddoe VW, Ar-
ends LR, Hofman A, et al. No midpregnancy fall in 
diastolic blood pressure in women with a low edu-
cational level: the Generation R Study. Hypertension 
2008;52: 645-51. 
  8. Kim EH, Lim JH, Kim YH, Park YW. The relation-
sHTNP between aldosterone to rennin ratio and RI 
value of the uterine artery in the preeclamptic patient 
vs. normal pregnancy. Yonsei Med J 2008;49: 138-43.
  9. Sandrim VC, Palei AC, Cavalli RC, Araujo FM, Ra-
mos ES, Duarte G, et al. eNOS haplotypes associated 
ΠΕΡΙΛΗΨΗ: Η υπερτασική νόσος της κύησης (ΥΝΚ) ορίζεται ως η παρουσία συστολικής αρτηριακής πίεσης ≥ 140mmHg ή 
διαστολικής  ≥ 90mmHg σε δύο τουλάχιστον διαφορετικές μετρήσεις κατά της διάρκεια της εγκυμοσύνης. Έχουν καθιερωθεί 
διάφορες μορφές ΥΝΚ, ανάλογα με τις εκάστοτε κατευθυντήριες οδηγίες. Στις κατηγορίες αυτές περιλαμβάνονται η χρόνια 
(προϋπάρχουσα) υπέρταση, η υπέρταση της κύησης, η χρόνια υπέρταση με συνοδό υπέρταση κύησης, η μη ταξινομούμενη 
υπέρταση και η προεκλαμψία. Παρά το γεγονός ότι τα ακριβή αίτια και οι παθογενετικοί μηχανισμοί της ΥΝΚ παραμένουν 
σε μεγάλο βαθμό αδιευκρίνιστα, η βαρύτητα των επιπλοκών, στις οποίες περιλαμβάνονται η εκλαμψία και το σύνδρομο 
HELLP, απαιτούν τη μέγιστη επαγρύπνηση. Ο κλινικός ιατρός οφείλει να αντιμετωπίζει την ΥΝΚ σαν έναν βασικό παράγο-
ντα νοσηρότητας και θνησιμότητας τόσο για την εγκυμονούσα, όσο και για το έμβρυο και το νεογνό. Η έγκαιρη διάγνωση 
και θεραπευτική παρέμβαση είναι πρωταρχικής σημασίας και πρέπει να εφαρμόζονται σε κάθε περίπτωση. Στην παρούσα 
ανασκόπηση περιγράφονται οι πιθανοί παθογενετικοί μηχανισμοί που εμπλέκονται στην εμφάνιση της ΥΚΝ, οι διάφορες 
μορφές της και οι σύγχρονες διαθέσιμες θεραπευτικές επιλογές.
Λέξεις Kλειδιά: Υπέρταση, Κύηση, Προεκλαμψία, Σύνδρομο HELLP.
Υπερτασική νόσος στην κύηση:  
ταξινόμηση, διάγνωση και αντιμετώπιση.
Νίκη Κατσίκη, Δημήτριος Γοδόσης, Σπυρίδων Κωμαΐτης, Απόστολος Χατζητόλιος
Τμήμα Αγγειακών Παθήσεων και Υπέρτασης, Α΄ Προπαιδευτική Παθολογική Κλινική,  
Νοσοκομείο ΑΧΕΠΑ, Αριστοτέλειο Πανεπιστήμιο Θεσσαλονίκης
rEFErEncES
 Hypertension in Pregnancy 17
with gestational hypertension or preeclampsia. Phar-
macogenomics 2008;9: 1467-73.
10. Zhao S, Gu Y, Dong Q, Fan R, Wang Y. Altered in-
terleukin-6 receptor, IL-6R and gp130, production 
and expression and decreased SOCS-3 expression in 
placentas from women with pre-eclampsia. Placenta 
2008;29: 1024-8. 
11. Raijmakers MT, Roes EM, Poston L, Steegers EA, 
Peters WH. The transient increase of oxidative stress 
during normal pregnancy is higher and persists after 
delivery in women with pre-eclampsia. Eur J Obstet 
Gynecol Reprod Biol 2008;138: 39-44. 
12. Gohlke-Baerwolf C, Eichstaedt H. Herzerkrankungen 
und Schwangerschaft. In: Roskamm H, Neumann FJ, 
Kalusche D, Bestehorn HP. Herzkrankheiten. Spring-
er, Berlin, Heidelberg, New York, 5. Aufl. 2004: 1285-
90.
13. Klein HH, Pich S. Cardiovascular changes during 
pregnancy. Herz 2003;28: 173-4.
14. Oakley C, Child A, Iung B, Presbitero P, Tornos P. Ex-
pert consensus document on management of cardio-
vascular diseases during pregnancy. Eur Heart J 2003; 
24: 761-81.
15. Weiss BM, Hess OM. Pulmonary vascular disease and 
pregnancy: current controversies, management strate-
gies, and perspectives. Eur Heart J 2000;21:104-115
16. Thäle V, Schlitt A. Hypertensive Erkrankungen in der 
Schwangerschaft. Internist 2008;49: 811-6.
17. Frishman WH, Schlocker SJ, Awad K, Tejani N. 
Pathophysiology and medical management of sys-
temic hypertension in pregnancy. Card Rev 2005;13: 
274-84.
18. Wagner SJ, Barac S, Garovic VD. Hypertensive preg-
nancy disorders: current concepts. J Clin Hypertens 
(Greenwich) 2007;9: 560-6.
19. Walker JJ. Pre-eclampsia. Lancet 2000; 356: 1260-5.
20. Kaplan N, Victor R. Hypertension with pregnancy and 
the pill. In Kaplan N, Victor R, eds. Kaplan’s Clinical 
Hypertension. Philadelphia: Lippincott Williams and 
Wilkins, 2010: 410-29.
21. Valensise H, Vasapollo B, Gagliardi G, Novelli GP. 
Early and late preeclampsia: two different maternal 
hemodynamic states in the latent phase of the disease. 
Hypertension 2008;52: 873-80. 
22. Karumanchi SA, Lindheimer MD. Preeclampsia 
pathogenesis: “triple a rating”-autoantibodies and an-
tiangiogenic factors. Hypertension 2008; 51: 991-2.
23. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs 
BP, et al. Soluble endoglin and other circulating an-
tiangiogenic factors in preeclampsia. N Engl J Med 
2006; 355: 992-1005.
24. Girndt J. Hochdruck und hypertensiver Notfall in der 
Schwangerschaft. Herz 2003;28: 185-95.
25. National High Blood Pressure Education Program 
Working Group NWG. Report of the National High 
Blood Pressure Education Program Working Group on 
High Blood Pressure in Pregnancy. Am J Obstet Gyne-
col 2000;183: 1-22.
26. James PR, Nelson-Piercy C. Management of hyperten-
sion before, during, and after pregnancy. Heart 2004; 
90: 1499-504.
27. Rath W. Hypertensive Schwangerschaftserkrankun-
gen. In: Rath W, Friese K (Hrsg). Erkrankungen in 
der Schwangerschaft. Thieme-Verlag, Stuttgart, New 
York, 2005: 73-97.
28. Duley L, Henderson-Smart DJ, Meher S, King JF. An-
tiplatelet agents for preventing pre-eclampsia and its 
complications. Cochrane Database Syst Rev 2007;18: 
CD004659.
29. Hay JE. Liver disease in pregnancy. Hepatology 2008; 
47: 1067-76. 
30. Hepburn IS, Schade RR. Pregnancy-associated liver 
disorders. Dig Dis Sci 2008;53: 2334-58. 
31. van Runnard Heimel PJ, Kavelaars A, Heijen CJ, Pe-
ters WH, Huisjes AJ, Franx A, et al. HELLP syndrome 
is associated with an increased inflammatory response, 
which may be inhibited by administration of predniso-
lone. Hypertens Pregnancy 2008;27: 252-65.
32. Haram K, Svendsen E, Abildgaard U. The HELLP 
syndrome: clinical issues and management. A review. 
BMC Pregnancy Childbirth 2009;9: 8.
33. Sibai BM. Chronic hypertension in pregnancy. Obstet 
Gynecol 2002;100: 369-77.
34. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, 
Burnier M, Caulfield MJ, et al. Reappraisal of Euro-
pean guidelines on hypertension management: a Euro-
pean Society of Hypertension Task Force document. J 
Hypertens 2009;27: 2121-58. 
35. Rath W, Heilmann L, Faridi A, Klockenbusch W. Emp-
fehlungen zur Diagnostik und Therapie des Bluthoch-
drucks in der Schwangerschaft. Frauenartzt 2002;43: 
847-51.
36. Sibai BM. Treatment of hypertension in pregnant 
women. N Engl J Med 1996; 335: 257-65.
37. Ghanem FA, Movahed A. Use of antihypertensive 
drugs during pregnancy and lactation. Cardiovasc 
Ther 2008;26: 38-49.
38. Steer PJ, Little MP, Kold-Jensen T, Chapple J, Elliott 
P. Maternal blood pressure in pregnancy, birth weight, 
and perinatal mortality in first births: prospective sru-
dy. BMJ 2004;329: 1312.
39. von Dadelszen P, Ornstein MP, Bull SB, Logan AG, 
Koren G, Magee LA. Fall in mean arterial pressure 
and fetal growth restriction in pregnancy hyperten-
sion: a meta-analysis. Lancet 2000;355: 87-92.
40. Magee LA, Ornstein MP, von Dadelszen P. Fortnightly 
review: management of hypertension in pregnancy. 
BMJ 1999;318: 1332-6.
18 Aristotle University Medical Journal, Vol. 37, Issue 2, June 2010
41. Brown MA, Hague WM, Higgins J, Lowe S, McCow-
an L, Oats J, et al. The detection, investigation and 
management of hypertension in pregnancy: full con-
sensus statement. Aust N Z J Obstet Gynaecol 2000; 
40: 139-55.
42. Redman CW. Controlled trials of antihyperten-
sive drugs in pregnancy. Am J Kidney Dis 1991;17: 
149-53.
43. Schaefer C, Weber - Schoendorfer C. Pharmako-
therapie in der Schwangerschaft. Internist 2009;50: 
455-66.
44. Weber-Schoendorfer C, Hannemann D, Meister R, 
Elefant E, Cuppers-Maarschalkerweerd B, Arnon J, 
et al. The safety of calcium channel blockers during 
pregnancy: a prospective, multicenter, observational 
study. Reprod Toxicol 2008;26: 24-30. 
45. Lydakis C, Lip GY, Beevers M, Beevers DG. Atenolol 
and fetal growth in pregnancies complicated by hyper-
tension. Am J Hypertension 1999;12: 541-7.
46. Vigil-De Gracia P, Lasso M, Ruiz E, Vega-Malek JC, 
de Mena FT, Lopez JC. Severe hypertension in preg-
nancy: hydralazine or labetalol. A randomized clini-
cal trial. Eur J Obstet Gynecol Reprod Biol 2006;128: 
157-62.
47. Barron WM, Lindheimer MD. Management of hyper-
tension during pregnancy. In: Laragh JH, Brenner BM, 
eds. Hypertension: Pathophysiology, Diagnosis and 
Management, 2nd ed. New York: Raven Press Ltd; 
1995 2427-2450.
48. Magee LA, Cham C, Waterman EJ, Ohlsson A, von 
Dadelszen P. Hydralazine for treatment of severe hy-
pertension in pregnancy: meta-analysis. BMJ 2003; 
327: 955-60.
49. Caetano M, Ornstein M, von Dadelszen P, Hannah 
ME, Logan AG, Gruslin A, et al. A survey of Canadian 
practitioners regarding the management of the hyper-
tensive disorders of pregnancy. Hypertens Pregnancy 
2003;23: 61-74.
50. Magee LA, von Dadelszen P. The management of se-
vere hypertension. Semin Perinatol 2009; 33: 138-42.
51. McCoy S, Baldwin K. Pharmacotherapeutic options 
for the treatment of preeclampsia. Am J Health Syst 
Pharm 2009;66: 337-44.
52. Doyle LW, Crowther CA, Middleton P, Marret S, 
Rouse D. Magnesium sulphate for women at risk of 
preterm birth for neuroprotection of the fetus. Co-
chrane Database Syst Rev 2009;1: CD004661. 
53. Pryde PG, Mittendorf R. Contemporary usage of ob-
stetric magnesium sulphate: indication, contraindi-
cation and relevance of dose. Obstet Gynecol 2009; 
114: 669-73.
54. Cooper WO, Hernandez-Diaz S, Aborgast PG. Major 
congenital malformations after first-trimester exposure 
to ACE inhibitors. N Engl J Med 2006;354: 2443-51.
55. Shotan A, Widehorn J, Hurst A, Elkayam U. Risks 
of angiotensin-converting enzyme inhibition during 
pregnancy: experimental and clinical evidence, poten-
tial mechanisms, and recommendations for use. Am J 
Med 1994;96: 451-6.
56. American Academy of Pediatrics Committee on Drugs. 
The transfer of drugs and other chemicals into human 
milk. Pediatrics 1994;93: 137-50.
57. Beardmore KS, Morris JM, Gallery ED. Excretion of 
antihypertensive medication into human breast milk: 
a systematic review. Hypertens Pregnancy 2002;21: 
85-95.
